Back to top

Immunovant price target raised to $61 from $57 at Citi

Citi raised the firm’s price target on Immunovant (IMVT) to $61 from $57 and keeps a Buy rating on the shares. Published first on TheFly – the ulti...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Immunovant, Inc. (IMVT)